Takeda Pharmaceutical (TAK) Tax Provisions (2017 - 2026)

Takeda Pharmaceutical's Tax Provisions history runs 10 years deep, the most recent figure standing at $676.9 million for Q1 2026.

• On a quarterly basis, Tax Provisions rose 350.05% year-over-year to $676.9 million in Q1 2026; TTM through Mar 2026 was $309.6 million, a 143.0% increase from a year earlier, with the FY2026 full-year figure at $64.9 million, down 85.23% from the prior year.
• Tax Provisions advanced to $676.9 million in Q1 2026 per TAK's latest filing, from $562.7 million in the prior quarter.
• Across five years, Tax Provisions topped out at $676.9 million in Q1 2026 and bottomed at -$734.0 million in Q1 2022.
• The 5-year median for Tax Provisions is -$270.7 million (2025), against an average of -$109.8 million.
• Across the five-year window, Tax Provisions sank 267.46% in 2022 and jumped 1692.2% in 2023, its largest moves.
• Year by year, Tax Provisions stood at $84.9 million in 2022, then surged by 254.55% to $301.1 million in 2023, then retreated by 2.77% to $292.7 million in 2024, then jumped by 92.24% to $562.7 million in 2025, then gained by 20.29% to $676.9 million in 2026.
• Per Business Quant, the three latest TAK Tax Provisions figures stand at $676.9 million (Q1 2026), $562.7 million (Q4 2025), and -$654.2 million (Q3 2025).